A review of lower urinary tract symptoms in patients with Parkinson's disease

Current Urology Reports

Volumn 15, Issue 9, 2014, Pages

  Badri, Anand V ^a,b   Purohit, Rajveer S ^b,c   Skenazy, Jason ^a   Weiss, Jeffrey P ^a,b   Blaivas, Jerry G ^a,b,c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Institute for Bladder and Prostate Research   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bladder outlet obstruction; BPH; Lower urinary tract symptoms; Overactive bladder; Parkinson's disease; Urinary symptoms

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

BEHAVIOR THERAPY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMORBIDITY; CONSERVATIVE TREATMENT; DISEASE ASSOCIATION; HUMAN; INTERVENTION STUDY; LIFESTYLE MODIFICATION; LOWER URINARY TRACT SYMPTOM; MEDICAL EXAMINATION; MEDICAL HISTORY; MEDLINE; MICTURITION DISORDER; MINIMALLY INVASIVE PROCEDURE; OVERACTIVE BLADDER; PARKINSON DISEASE; POSTOPERATIVE COMPLICATION; PREVALENCE; QUALITY OF LIFE; REVIEW; URINE RETENTION; UROLOGIC EXAMINATION; BLADDER; BLADDER CATHETERIZATION; COMPLICATION; ELECTROSTIMULATION THERAPY; FEMALE; LOWER URINARY TRACT SYMPTOMS; MALE; PATHOPHYSIOLOGY; PROCEDURES; SURGERY; TIBIAL NERVE; TRANSURETHRAL RESECTION; URINARY BLADDER NECK OBSTRUCTION; URINARY BLADDER, OVERACTIVE; URINARY DIVERSION;

CHOLINERGIC ANTAGONISTS; DOPAMINE AGENTS; ELECTRIC STIMULATION THERAPY; FEMALE; HUMANS; LEVODOPA; LOWER URINARY TRACT SYMPTOMS; MALE; PARKINSON DISEASE; TIBIAL NERVE; TRANSURETHRAL RESECTION OF PROSTATE; URINARY BLADDER; URINARY BLADDER NECK OBSTRUCTION; URINARY BLADDER, OVERACTIVE; URINARY CATHETERIZATION; URINARY DIVERSION;

EID: 84903664236     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-014-0435-0     Document Type: Review

References (43)

1. Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 2006; 9.
2. • Kapoor S, Bourdoumis A, Mambu L, Barua J. Effective management of lower urinary tract dysfunction in idiopathic Parkinson's Disease. Int J Urol. 2013;20(1):79-84. This article represents an effective and useful literature review of the urologic sequelae of PD. Taking data from 2012 and earlier, the group presents a cohesive, systematic approach to managing LUTS in PD.
3. Fowler CJ, Dalton C, Panicker JN. Review of neurologic diseases for the urologist. Urol Clin N Am. 2010;37:517-26.
4. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4.
5. Blaivas JG, Panagopolous G, Weiss JP, Somaroo C, Chaikin DC. The Urgency Perception Score: Validation and Test-Retest. J Urol. 2007;177:199-202. (Pubitemid 44879459)
6. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;6:453-66. (Pubitemid 351704950)
7. Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson 's disease: A review. Parkinsonism Relat disord. 2009;15(2):81-7.
8. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry. 2000;68:429-33. (Pubitemid 30248741)
9. Lemack GE, Dewey RB, Roehrborn CG, et al. Questionnaire-based assessment of bladder dysfunction in patients withmild tomoderate Parkinson's disease. Urology. 2000;56:250-4. (Pubitemid 30495577)
10. Sakakibara R, Uchiyama T, Yamanishi T, et al. Bladder and bowel dysfunction in Parkinson's Disease. J Neural Transm. 2008;115: 443-60.
11. Ransmayr GN, Holliger S, Schletterer K, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008;70:299-303. (Pubitemid 351156810)
12. Berger Y, Blaivas JG, DeLaRocha ER, Salinas EM. Urodynamic findings in Parkinson's Disease. J Urol. 1987;138(4):836-8. (Pubitemid 17150774)
13. Ragab MM, Mohammed ES. Idiopathic Parkinson's disease patients at the Urologic Clinic. Neurourol Urodyn. 2011;20:1258-61.
14. •• Siegl E, Lassen B, Saxer S. "Incontinence - a common issue for people with Parkinson's disease. A systematic literature review". [Article in German]. Pflege Z. 2013;66(9):540- 4. -This review sought to look into the literature to determine the incidence of urinary and fecal incontinence as well as different measures for treatment or improvement. -Consisted of a review of three studies with a total sample size of n = 1077. Comparing urge incontinence between women with and without PD, they found an incidence of 25% and 7%, respectively. Similarly, they found an incidence of 28% and 6% in men with and without PD, respectively. -Suggest that pelvic floor muscle exercises as well as botulinum toxin A injections can reduce urinary incontinence, but the review doesn't offer recommendations.
15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181.
16. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol. 2004;3:93.
17. Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain. 2004;127:2657.
18. Kircchof K, Apostolidis AN, Mathias CJ, Fowler CJ. Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study. Int J Impot Res. 2003;15:293-8.
19. Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol. 1997;80:100-4. (Pubitemid 28316716)
20. Salinas JM, Berger Y, De La Rocha RE, Blaivas JG. Urological evaluation in the Shy Drager Syndrome. J Urol. 1986;135(4):741-3. (Pubitemid 16111140)
21. Gancher ST. Modified Hoehn And Yahr Staging. In: Factor SA, Weiner WJ, editors. Parkinson's Disease: Diagnosis and Clinical Management. New York: Demos Medical Publishing; 2002.
22. Weiss JP, Blaivas JG, Tash Anger JA, Di Blasio CJ, Panagopoulos G, Gerboc J. Development and validation of a new treatment outcome score for men with LUTS. Neurourol Urodyn. 2004;23(2):88-93. (Pubitemid 38296191)
23. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003), Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530.
24. Tsui JF, Shah MB, Weinberger JM, Ghanaat M, Weiss JP, Purohit RS, et al. Pad count is a poor measure of the severity of urinary incontinence. J Urol. 2013;190(5):1787-90.
25. Nitti VW. Pressure Flow Urodynamic Studies: The Gold Standard for Diagnosing Bladder Outlet Obstruction. Rev Urol. 2005;7 Suppl 6:S14-21.
26. Dmochowski RR. Bladder outlet obstruction: etiology and evaluation. Rev Urol. 2005;7 Suppl 6:S3.
27. Flisser AJ, Walmsley K, Blaivas JG. Urodynamic classification of patients with symptoms of overactive bladder. J Urol. 2003;169(2): 529-33. discussion 533-4.
28. Santos-Garcia D, de la Fuente-Fernandez R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease. J Neurol Sci. 2013;332(1-2):136-40.
29. •• Perez-Lloret S, Rey MV, Pavy-Le Traon A, Rascol O. Emerging drugs for autonomic dysfunction in Parkinson's disease. Expert Opin Emerg Drugs. 2013;18(1):39-53. -Pharmacotherapeutical article assessing multiple drugs for PD-associated autonomic dysfunction. -Specifically for this review, compared muscarinic antagonists for women with urge incontinence. In order of decreasing efficacy (#women with restored continence/1000): fesoterodine → oxybutynin (Only one that's FDA approved although less efficacious) → trospium → solifenacin → tolterodine. -Botulinum Toxin A - positive effect for incontinence, detrusor overactivity, painful bladder syndrome, BPH. -Suggests need for further study based on IPSS and DanPSS for subjectivity and weighing protective pads for incontinence testing pre/post treatment for objectivity.
30. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: Mechanisms, Prevalence, Symptoms and Management. Mov Dis. 2006;21:737-45. (Pubitemid 44028290)
31. Winge K, Werdelin L, Nielsen K, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn. 2004;23:689-96. (Pubitemid 39313943)
32. •• Cone EB, Ellsworth P. Neurogenic detrusor overactivity: an update on management options. R I Med J. 2013;96(4):38-40. -Paper good for informing clinicians about mechanisms of treatments and the treatments available in a stepwise form from least to most invasive. -Goals should be 1) prevent upper tract damage and 2) improve symptoms/quality of life/independent living.
33. Giannantoni A, Conte A, Proietti S, et al. Botulinumtoxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol. 2011;186:960-4.
34. Anderson RU, Orenberg EK, Glowe P. Onabotulinumtoxin A office treatment for neurogenic bladder incontinence in Parkinson's disease. Urology. 2014;83(1):22-7.
35. .• Phé V, Caremel R, Bart S, Castel-Lacanal E, de Sèze M, Duchêne F, et al. le Comité de neuro-urologie de l'Association française d'urologie. "Lower urinary tract dysfunctions in parkinsonian syndromes: a review by the Neuro-Urology Comittee of the French Association of Urology. " [Article in French]. Prog Urol. 2013;23(5):296-308. -A review of LUTS in parkinsonian syndromes completed by the French Association of Urology. -The review discussed the efficacy of Posterior Tibial Nerve Stimulation very well.
36. Ohannessian A, Kaboré FA, Agostini A, Lenne Aurier K, Witjas T, Azulay JP, et al. Transcutaneous tibial nerve stimulation in the overactive bladder syndrome in patients with Parkinson's syndromes. Prog Urol. 2013;23(11):936-9.
37. Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988;140(1):117-8.
38. Roth B, Studer UE, Fowler CJ, Kesslet TM. Benign prostatic obstruction and parkinson's disease - should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209-13.
39. Reyblat P, Ginsberg DA. Augmentation Cystoplasty: what are the indications? Curr Urol Rep. 2008;9(6):452-8.
40. Pannek J, Stohrer M, Blok B et al. Guidelines on neurogenic lower urinary tract dysfunction. EAU Guidelines. 2012;pp. 8-36.
41. •• Ashkan K, Samuel M, Reddy P, Ray CK. The impact of deep brain stimulation on the nonmotor symptoms of Parkinson's disease. J Neural Transm. 2013;120(4):639-42. -This paper suggests that "DBS has a major potential to contribute towards the holistic care of PD patients." This is in light of an increase in the ability to more objectively assess the effect of DBS on the nonmotor burden in PD pts. -Nonmotor Symptoms Screening Questionnaire (NMSQuest) is a 30-item validated questionnaire to assess nonmotor burden in 545 pts with PD pre/post DBS. -Suggest that DBS shows no worsening of symptomatology. -Adverse effects include: transient psychiatric and mood disturbance (depression, hypomania, delirium), apathy, impaired verbal fluency, and impulse control disorders. Mechanism unclear, but may involve lesioning effect of frontostriatal circuits along the trajectory of the electrode, suboptimal positioning of the electrodes, current spread to adjacent structures, or non-judicial post-surgical medication adjustment.
42. Wolz M, Hauschild J, Fauser M, et al. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2012;18: 994-7.
43. •• Winge K, Nielsen KK. Bladder dysfunction in advanced Parkinson's disease. Neurourol Urodyn. 2012;31(8):1279-83. - Aim: To assess severity of bladder dysfunction in PD as stratified by symptomatic treatment, specifically DBS and Apomorphine vs medical treatment. - Used two validated questionnaires: DanPSS and IPSS. Used these to assess symptomatology and impact on quality of life. - The analysis found that in the conventional group, the severity of bladder dysfunction (DanPSS ≥ 10) correlated with a greater PD stage (based on the modified Hoehn and Yahr PD staging from 0 to 5). This did not hold for the nonconventional group, however, which included those treated with DBS or apomorphine and also did not hold when given the IPSS validated questionnaire. - They completed a further analysis based on specific symptoms and found that DBS patients had significantly less nocturia (as defined by > 2 episodes of voiding per night) and were less bothered by it. - Drawbacks: ○ Definition of nocturia in the DanPSS isn't rigorous as the established ICS definition of nocturia (minimum one episode of waking to void that is preceded and followed by sleep) ○ Low N in general (N=107), but specifically in Apomorphine group (n=9). Unable to draw substantial conclusions from such a low sample size. ○ Only looked into questionnaire-based evaluation. Lacks the objectivity of other studies, as it doesn't include urodynamic testing, etc.